RLAY
Relay Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +30.0% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 94 | +5 | 111.06M | $2.04B | +12 | −7 |
| Q1 2026 | 92 | +9 | 68.30M | $679.13M | +15 | −7 |
| Q4 2025 | 84 | +2 | 73.82M | $624.52M | +3 | — |
| Q3 2025 | 14 | -1 | 56.07M | $292.70M | — | −2 |
| Q2 2025 | 13 | 0 | 54.62M | $188.99M | +1 | −1 |
| Q1 2025 | 10 | -2 | 33.93M | $88.91M | — | −2 |
| Q4 2024 | 12 | 0 | 26.38M | $108.69M | — | — |
| Q3 2024 | 11 | 0 | 24.01M | $170.03M | +2 | −2 |
| Q2 2024 | 11 | — | 15.37M | $100.25M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Norges Bank ✦ (passive) | 5.92M | +78.3% | $41.90M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 5.28M | +4.8% | $37.38M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 5.28M | +4.8% | $37.38M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 2.91M | +150.1% | $20.60M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 2.91M | +150.1% | $20.60M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 2.73M | +15.5% | $19.35M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 2.73M | +15.5% | $19.35M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 1.65M | New | $11.68M | 0.0% | New | 1 | SEC ↗ |
| 9 | Marshall Wace ✦ | 1.41M | +408.0% | $9.95M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Marshall Wace ✦ | 1.41M | +408.0% | $9.95M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Point72 Asset Management ✦ | 1.35M | New | $9.55M | 0.0% | New | 1 | SEC ↗ |
| 12 | Millennium Management ✦ | 1.06M | -7.8% | $7.50M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 1.02M | +39.1% | $7.19M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 671.10K | -26.2% | $4.75M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 23.39K | -65.2% | $165,615 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 23.39K | -65.2% | $165,615 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 23.39K | -65.2% | $165,615 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $11.68M | 0.0% |
| Point72 Asset Management | $9.55M | 0.0% |
Exited
| Baillie Gifford | $1.85M | was 0.0% |
| Wellington Management | $468,873 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 240 holders, 183.00M shares, $1.79B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 17.72K sh · $349,734
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology